Meda acquires five GlaxoSmithKline OTC products for the US market
This article was originally published in Scrip
Sweden's Meda acquired two more OTC drugs for the US market from GlaxoSmithKline for SEK180 million ($27 million) at the beginning of January after buying three US OTC products for SEK235 million in December. The acquired products were Vivarin (caffeine), the anti-anaemics Feosol and Palafer (iron salts), the vitamin mixture Geritol and Contac (pseudoephedrine hydrochloride), a treatment for a blocked nose and sinus congestion associated with allergies, colds and flu. Their combined annual sales in the US are worth around SEK180 million.
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.